Objective: to explore the clinical value of esomeprazole combined with magnesium aluminum in the treatment of gastric ulcer. Methods: a total of 80 patients with gastric ulcer admitted from April 2020 to April 2021 we...Objective: to explore the clinical value of esomeprazole combined with magnesium aluminum in the treatment of gastric ulcer. Methods: a total of 80 patients with gastric ulcer admitted from April 2020 to April 2021 were selected and divided into observation group and control group, 40 cases in each group. Control group was treated with esomeprazole alone, and observation group and control group were treated with magnesium aluminum. The two groups were compared for treatment indicators: total rate of treatment, clinical symptoms, hyperhealing effect, inflammatory factor levels, changes in exercise and stomach levels, and adverse reactions. Result: the total effective rate in the observation group was 95.00% higher than that in the control group (77.50%). Meanwhile, the improvement time of symptoms such as vomiting blood, hematochezia, abdominal pain, abdominal distension and belching was significantly shorter than that in the control group (P < 0.05). The levels of VEGF, EGF and COX and inflammatory factors (IL-6 and CRP) in gastric mucosa ulceration in 2 groups were significantly improved after treatment, and the levels of VEGF, EGF and COX in observation group were higher than those in control group, while il-6 and CRP were lower (P < 0.05). The levels of gastrin and motilin in 2 groups before treatment were significantly decreased after treatment (P > 0.05), and the levels of gastrin and motilin in observation group were significantly lower than those in control group (P < 0.05). There was no statistical difference in the rate of adverse reactions between 2 groups (P > 0.05). Conclusion: esomeprazole combined with magnesium aluminum carbonate in the treatment of gastric ulcer can achieve more ideal therapeutic effect, improve symptoms, promote gastric mucosal repair and healing, and the safety of treatment is guaranteed.展开更多
文摘Objective: to explore the clinical value of esomeprazole combined with magnesium aluminum in the treatment of gastric ulcer. Methods: a total of 80 patients with gastric ulcer admitted from April 2020 to April 2021 were selected and divided into observation group and control group, 40 cases in each group. Control group was treated with esomeprazole alone, and observation group and control group were treated with magnesium aluminum. The two groups were compared for treatment indicators: total rate of treatment, clinical symptoms, hyperhealing effect, inflammatory factor levels, changes in exercise and stomach levels, and adverse reactions. Result: the total effective rate in the observation group was 95.00% higher than that in the control group (77.50%). Meanwhile, the improvement time of symptoms such as vomiting blood, hematochezia, abdominal pain, abdominal distension and belching was significantly shorter than that in the control group (P < 0.05). The levels of VEGF, EGF and COX and inflammatory factors (IL-6 and CRP) in gastric mucosa ulceration in 2 groups were significantly improved after treatment, and the levels of VEGF, EGF and COX in observation group were higher than those in control group, while il-6 and CRP were lower (P < 0.05). The levels of gastrin and motilin in 2 groups before treatment were significantly decreased after treatment (P > 0.05), and the levels of gastrin and motilin in observation group were significantly lower than those in control group (P < 0.05). There was no statistical difference in the rate of adverse reactions between 2 groups (P > 0.05). Conclusion: esomeprazole combined with magnesium aluminum carbonate in the treatment of gastric ulcer can achieve more ideal therapeutic effect, improve symptoms, promote gastric mucosal repair and healing, and the safety of treatment is guaranteed.
